Stock BAYN BAYER AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra
Other stock markets
 11:36:55 2024-05-31 am EDT 		5-day change 1st Jan Change
28.24 EUR +0.66% Intraday chart for Bayer AG +2.21% -16.03%
May. 30 German Shares Edge Up as Eurozone Sentiment Data Improves MT
May. 30 Burning Rock Biotech to Work With Bayer to Increase Patient Access to Precision Cancer Medicines in China MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 71,530 47,309 46,174 47,476 33,039 27,744 - -
Enterprise Value (EV) 1 105,598 84,884 79,140 78,749 67,302 61,746 58,235 54,836
P/E ratio 17.5 x -4.51 x 46.1 x 11.5 x -11.2 x 12.4 x 8.66 x 8.28 x
Yield 3.85% 4.15% 4.26% 4.97% 0.33% 0.39% 0.77% 3.87%
Capitalization / Revenue 1.64 x 1.14 x 1.05 x 0.94 x 0.69 x 0.59 x 0.58 x 0.57 x
EV / Revenue 2.43 x 2.05 x 1.8 x 1.55 x 1.41 x 1.31 x 1.22 x 1.13 x
EV / EBITDA 9.18 x 7.41 x 7.08 x 5.83 x 6.33 x 5.92 x 5.38 x 4.99 x
EV / FCF 19 x 34.2 x 31.9 x 19 x 28.4 x 18.3 x 11.9 x 12.5 x
FCF Yield 5.26% 2.93% 3.13% 5.26% 3.52% 5.47% 8.39% 8.02%
Price to Book 1.51 x 1.55 x 1.4 x 1.22 x 1 x 0.82 x 0.74 x 0.67 x
Nbr of stocks (in thousands) 982,424 982,424 982,424 982,424 982,424 982,424 - -
Reference price 2 72.81 48.16 47.00 48.32 33.63 28.24 28.24 28.24
Announcement Date 2/27/20 2/25/21 3/1/22 2/28/23 3/5/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 43,545 41,400 44,081 50,739 47,637 47,119 47,903 48,603
EBITDA 1 11,503 11,461 11,179 13,513 10,632 10,426 10,828 10,987
EBIT 1 7,007 7,095 7,295 9,257 7,589 6,673 7,051 7,205
Operating Margin 16.09% 17.14% 16.55% 18.24% 15.93% 14.16% 14.72% 14.82%
Earnings before Tax (EBT) 1 2,880 -17,250 2,046 4,670 -1,621 3,786 4,026 4,364
Net income 1 4,091 -10,495 1,000 4,150 -2,941 2,334 3,179 3,394
Net margin 9.39% -25.35% 2.27% 8.18% -6.17% 4.95% 6.64% 6.98%
EPS 2 4.170 -10.68 1.020 4.220 -2.990 2.285 3.260 3.410
Free Cash Flow 1 5,557 2,485 2,478 4,144 2,366 3,376 4,884 4,395
FCF margin 12.76% 6% 5.62% 8.17% 4.97% 7.17% 10.19% 9.04%
FCF Conversion (EBITDA) 48.31% 21.68% 22.17% 30.67% 22.25% 32.38% 45.1% 40.01%
FCF Conversion (Net income) 135.83% - 247.8% 99.86% - 144.63% 153.64% 129.51%
Dividend per Share 2 2.800 2.000 2.000 2.400 0.1100 0.1110 0.2174 1.092
Announcement Date 2/27/20 2/25/21 3/1/22 2/28/23 3/5/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2
Net sales 1 22,899 18,501 11,118 14,639 12,819 11,281 12,000 14,389 11,044 10,342 11,862 13,765 11,052 24,831 10,376 11,963 22,454 - -
EBITDA 1 7,274 - 2,395 5,251 3,349 2,451 2,462 4,471 2,527 1,685 3,023 4,412 2,337 6,738 1,569 2,337 3,941 - -
EBIT 1 - - 1,383 4,172 2,280 1,352 1,453 3,404 1,534 709 1,942 3,299 1,269 - 788.9 1,280 - - -
Operating Margin - - 12.44% 28.5% 17.79% 11.98% 12.11% 23.66% 13.89% 6.86% 16.37% 23.97% 11.48% - 7.6% 10.7% - - -
Earnings before Tax (EBT) - - 1,497 3,722 -523 601 870 2,606 -1,574 -4,297 1,644 - - - - - - - -
Net income 1 - - 1,161 3,291 -298 546 611 2,178 -1,887 -4,569 1,337 2,000 84.53 - -305.8 -201.4 - - -
Net margin - - 10.44% 22.48% -2.32% 4.84% 5.09% 15.14% -17.09% -44.18% 11.27% 14.53% 0.76% - -2.95% -1.68% - - -
EPS 2 - - 1.180 3.350 -0.3000 0.5600 0.6200 2.220 -1.920 -4.660 1.360 2.040 0.0854 - -0.3110 -0.2052 - - -
Dividend per Share 2 - - 2.000 - - - 2.400 - - - 0.1100 - 0.0275 - 0.0275 0.0275 - 0.0275 0.0275
Announcement Date 8/4/20 2/25/21 3/1/22 5/10/22 8/4/22 11/8/22 2/28/23 5/11/23 8/8/23 11/8/23 3/5/24 5/14/24 - - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 34,068 37,575 32,966 31,273 34,263 34,002 30,491 27,092
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.962 x 3.279 x 2.949 x 2.314 x 3.223 x 3.261 x 2.816 x 2.466 x
Free Cash Flow 1 5,557 2,485 2,478 4,144 2,366 3,376 4,884 4,395
ROE (net income / shareholders' equity) 13.5% 16.2% 20.1% 8.65% 17.5% 14.5% 15% 13.5%
ROA (Net income/ Total Assets) 3.23% -8.63% 0.84% 3.39% -2.44% 0.73% 1.55% 2.62%
Assets 1 126,495 121,611 118,526 122,560 120,567 319,156 204,993 129,465
Book Value Per Share 2 48.20 31.10 33.60 39.50 33.50 34.50 38.30 42.30
Cash Flow per Share 2 8.360 4.990 5.180 7.220 5.210 6.210 8.350 8.320
Capex 1 2,650 2,418 2,611 2,949 2,751 2,996 2,912 2,987
Capex / Sales 6.09% 5.84% 5.92% 5.81% 5.77% 6.36% 6.08% 6.15%
Announcement Date 2/27/20 2/25/21 3/1/22 2/28/23 3/5/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bayer AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
28.24 EUR
Average target price
36.64 EUR
Spread / Average Target
+29.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BAYER AG Stock Bayer AG
-16.03% 30.09B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. Financials Bayer AG